CNTXContext Therapeutics Inc. Common Stock

0.5001USD+2.58%Mkt Cap: 45.95M $P/E:

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody …